Development and evaluation of screening dysphagia tools for observational studies and routine care in cancer patients

Michael Borean1 | Kishan Shani1 | M. Catherine Brown1 | Judy Chen1 | Mindy Liang1 | Joel Karkada1 | Simranjit Kooner1 | Mark K. Doherty2 | Grainne M. O’Kane1 | Raymond Jang1 | Elena Elimova1 | Rebecca K. Wong3 | Gail E. Darling4 | Wei Xu5 | Doris Howell6 | Geoffrey Liu1,7

1 Division of Medical Oncology Princess Margaret Cancer Centre and Departments of Medicine and Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
2 Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada
3 Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
4 Department of Thoracic Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada
5 Department of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
6 Psychosocial Oncology, Princess Margaret Cancer Centre, Lawrence Bloomberg School of Nursing, University of Toronto, Toronto, Ontario, Canada
7 Department of Epidemiology, Dalla Lana School of Public Health, Departments of Medicine and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

Correspondence
Geoffrey Liu, MD FRCP, Psychosocial Oncology, Princess Margaret Cancer Centre, Lawrence Bloomberg School of Nursing, University of Toronto, Toronto, Ontario M5S 1A1, Canada.
Email: geoffrey.liu@uhn.ca
Doris Howell, RN, PhD, Division of Medical Oncology Princess Margaret Cancer Centre and Departments of Medicine and Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario M5S 1A1 Canada.
Email: doris.howell@uhn.ca

Abstract

Background and aims: Dysphagia can be associated with significant morbidity in cancer patients. We aimed to develop and evaluate dysphagia screener tools for use in observational studies (phase 1) and for routine symptom monitoring in clinical care (phase 2).

Methods: Various dysphagia or odynophagia screening questions, selected after an expert panel reviewed the content, criterion, and construct validity, were compared with either functional assessment of cancer therapy - esophageal cancer (FACT-E) Swallowing Index Cut-Off Values or to questions adapted from the Patient Reported Outcomes for Common Terminology Criteria for Adverse Events. Sensitivity, specificity, and patient acceptability were assessed.

Results: In Phase 1 (n = 178 esophageal cancer patients), the screening question “How are you currently eating?” had the highest sensitivities and specificities against various Swallowing Index Cut-Off Value cut-offs, with the best optimal cutoff associated with weight loss (80% sensitivity and 75% specificity). In phase 2 (255 head and neck, gastro-esophageal, and thoracic cancer patients), a single question screener (“Do you experience any difficulty or pain upon swallowing?”) versus a Patient Reported Outcomes for Common Terminology Criteria for Adverse Events – gold standard generated sensitivities between 86% and 94% and specificities between 93% and 100%. This screening question (+/- follow-up questions) had a median completion time of under 2 minutes, and >90% of patients were willing to complete the survey electronically, did not feel that survey made clinic visit more difficult, and did not find the questions upsetting or distressful.

Conclusion: Our results demonstrate that these screener tools (“How are you currently eating?”, “Do you experience any difficulty or pain upon swallowing?”) can effectively screen dysphagia symptoms without increasing cancer outpatient clinic burden, both in observational studies and for routine clinical monitoring.
1 | INTRODUCTION

A patient-reported outcome (PRO) is any health status report that is provided directly by the patient, without interpretation of the patient’s response by a clinician or anyone else. Patient-reported outcomes can take on a variety of forms, including measurements of symptom severity and/or health-related quality of life (HRQoL). Patient-reported outcomes with a symptomatic focus are of the utmost importance in cancer care. Many cancer-related symptoms are associated with the disease, but some symptoms such as fatigue, neuropathy, and affective symptoms can also be caused by cancer therapy. Regardless of cause, when symptoms are not managed effectively, they can impact patients’ functional status, affect, and HRQoL.

Further, unrelieved symptoms can cause patients to interrupt or abandon treatment or decrease adherence to treatment regimens. As essential a role that symptom PROs play in multidisciplinary cancer care, barriers exist that may result in suboptimal symptom assessment. Outpatient clinics must balance the need for comprehensive symptom assessments, while minimizing patient burden. One method is to implement short symptom screener tools, followed by more comprehensive questions if the patient elicits a positive screen result; this may maximize symptom reporting while reducing clinic burden on both patients and clinicians.

Symptom screening may also have merits in the context of prospective observational studies. Unlike clinical trial patients, who are aware that they are potentially benefiting from specialized treatment regimens, patients enrolled in observational studies often perceive no direct benefits. These patients may lack motivation to complete long questionnaires—a burden that can be avoided with effective screening tools.

Although dysphagia (difficulty swallowing) is not one of the most prevalent symptoms in the general cancer population, it has high morbidity. Decreased HRQoL accompanies difficulty in eating or drinking. In the extreme setting, severe dysphagia managed by nasogastric feeding can lead to sustained symptoms due to muscle atrophy. Dysphagia is associated with malnutrition and a subsequent increased risk of infection. When dehydration occurs, renal failure and other adverse effects such as constipation are common, which can associate with impaired mental status and delirium. Mechanical obstructive tumors can lead to weight loss and shorter survival times.

Within certain cancer populations, dysphagia is highly prevalent: Dysphagia is observed in approximately 50% of head and neck patients; progressive dysphagia and/or odynophagia (pain upon swallowing) are the most common presenting symptoms in gastrointestinal cancer patients. Radiation-induced dysphagia and odynophagia occur in patients receiving radiation to the chest or mediastinum (the central compartment of the thoracic cavity), often up to 2 months posttreatment.

The main goals of this study were (1) to develop a dysphagia screening tool for use in both observational study screening and routine symptom monitoring, (2) to compare the tool’s sensitivity and specificity with gold-standard tools in capturing dysphagia symptoms, and (3) to assess the feasibility and acceptability of implementing our dysphagia screener tool on an electronic tablet (Apple’s iPad) in an outpatient clinic. Because we were devising screening tools for research purposes (observational study) and separately for routine symptom monitoring, we have discussed them separately in Sections 2 and 3, as phase 1 (research/observational study) and phase 2 (routine use).

2 | METHODS

2.1 | Study design and population

This study was approved by the Research Ethics Board of the University Health Network in Toronto, Ontario, Canada; informed consent was obtained from all participants. The purpose of the study was to develop dysphagia screening tools for prospective observational studies (phase 1) and for routine clinical care (phase 2). In both phases, an expert panel using a consensus approach reviewed potential screening and follow-up questions for criterion, content, and construct validity, as well as feasibility, where possible, validated gold standards were chosen. The phases were performed at separate times, with phase 2 occurring after the end of phase 1 recruitment.

2.2 | Stakeholder and expert panel for phases 1 and 2

Two panels were created because of the number of individuals required; individuals were randomly assigned to each panel (13 per panel), with one panel focused on phase 1 and the other panel on phase 2. Decisions of one panel were then introduced to the other panel for commentary and discussion. Individuals for the 2 panels included 3 gastrointestinal cancer clinic nurses from 2 Toronto institutions; 2 outpatient clinic nurses from institutions in Ottawa and Edmonton; 2 speech, swallowing, and language clinicians from Toronto and Houston; 2 PhD researchers focusing on esophageal and head and neck cancer translational research from Toronto and Vancouver; 1 PhD researcher focused on knowledge translational science (Calgary); 3 gastrointestinal cancer medical oncology fellows originally from 3 continents but currently training in Canada; 2 radiation oncology fellows from North America; 2 staff surgeons and 2 radiation oncologist staff; 3 medical oncology staff from 3 centers in North America; and 4 patient representatives, including one from the Canadian Cancer Society. There was 1 face-to-face initial meeting of a subset of both of these panels at the Canadian Clinical Trials Group Annual Meeting. Stakeholders then met in 2 formal 2-hour virtual meetings, with further communications performed online through electronic mail.

KEYWORDS
dysphagia, esophageal cancer, gastric cancer, head and neck cancer, lung cancer, patient-reported outcomes, symptom screening
2.3 Statistical analyses

Descriptive statistics were performed separately for phases 1 and 2, including median, minimum, and maximums for continuous variables, and frequency tabulations by categorical variables. All statistical analyses were conducted using SAS 9.4.

2.3.1 Phase 1 screeners for research purposes

In phase 1, when developing a screening tool useful for prospective observational studies, the primary objective was to identify a highly sensitive screening question for dysphagia to reduce the burden of completing the full validated FACT-E swallowing index (45 total questions and 8 swallowing-specific questions). The panel selected 2 potential single-screening questions: Screener 1, “How are you currently eating?”, was derived from O'Rourke et al., with response choices of “normal,” “eats soft food only,” “eats pureed food only,” “drinks liquid only,” and “no swallowing at all” (Figure 2), and for Screener 2, one of the FACT-E questions itself was chosen as a putative screening question: “I can swallow easily and naturally,” with response choices of “very much,” “quite a bit,” “somewhat,” “a little bit,” and “not at all.” Given a gold standard based on FACT-E that is focused on esophageal cancer patients, all phase 1 patients were restricted to those with a diagnosis of gastroesophageal cancer.

2.4 Recruitment and data collection procedures

At outpatient clinics, patients were prescreened for study eligibility by the clinical team. Patients over the age of 18 years with a gastroesophageal or esophageal cancer, who were capable of communicating in English and were deemed to be competent to understanding the study by their physicians, were deemed eligible. A life expectancy by their physicians of at least 12 weeks was also an eligibility criterion, as the institutional review board felt that approaching actively dying patients was unethical. Eligible patients were approached in clinic waiting areas and examination rooms prior to their appointments. In phase 1, patients completed screeners 1 and 2 along with the 5 question FACT-E Swallowing Index subset. The full questionnaire included clinico-demographic questions and the EQSD-3L, a 5-question tool that can be converted into a health utility score. All patients included in phase 1 completed the questionnaire on paper. Cancer clinical data for patients was abstracted from the electronic medical records. Clinicians were not given the dysphagia data but were asked to manage their patients in a usual fashion.

2.5 Statistical analysis

For phase 1, patients were considered screen-positive if they responded anything other than “normal” to Screener 1 or “very much” to Screener 2 (see Figure 2 for full response set). Sensitivities and specificities were calculated for each screener against various Swallowing Index Cut-off Values (SICVs), a summation of scores from 5 FACT-E questions (E1, E2, E3, E5, and HN7), with possible SICV values of 0 to 20; higher scores represented lower severity of symptoms. Negatively worded questions were reverse scored. Swallowing Index Cut-off Values were determined from clinical factors previously described by Darling et al., scores of 5.5 (2 standard deviations below mean of surgical cancer patients at 3-4 months follow-up), 7.1 (1 standard deviation below mean of cancer patients who experienced weight loss), 12.16 (mean of cancer patients who experienced weight loss), 13.3 (mean of surgical cancer patients), 14.5 (mean of surgical cancer patients at 3-4 months follow-up), and 16.0 (mean of cancer patients without pain). Receiver operating characteristic curves were generated using the same screener and these various SICV criteria.

2.5.1 Phase 2 screeners for routine clinical monitoring

In phase 2, the objective was to develop and evaluate practical, routine screening question(s) for detecting swallowing disturbances in routine cancer patient management. Similar to our previous evaluations, we used more comprehensive and focused symptom questions in the style of Patient Reported Outcomes for Common Terminology Criteria for Adverse Events (PRO-CTCAE). However, while PRO-CTCAE has a single question about dysphagia, our expert panel determined that for clinical management purposes, severity of symptoms and functional interference were both of clinical relevance; symptom frequency, however, was too confounded by a patient’s frequency of attempts at eating. The panel also identified that difficulty swallowing (dysphagia) and pain upon swallowing (odynophagia) of solids, and independently, of liquids, were important separate symptoms requiring different management and should be assessed separately. In the first part of phase 2, the evaluation was, therefore, of 2 separate screening questions, 1 for dysphagia (screener 3) and 1 for odynophagia (screener 4), and initially tested on patients in this manner. Upon a suggestion at a prespecified mid–phase 2 stakeholder and expert panel meeting, the 2 screening questions were later combined into a single screening question (screener 5): “Do you experience any difficulty or pain upon swallowing?”, with response choices of “no,” “difficulty swallowing only,” “pain swallowing only,” “both difficulty and pain swallowing”; the last half of the phase 2 section then utilized the 1 question screener (screener 5). With the purpose of screening for routine cancer care, dual assessments of feasibility/patient acceptability and sensitivity/specificity of the screener were performed. Given this same objective, patients with head and neck and gastroesophageal cancers, and those receiving mediastinal radiation, were chosen as test subjects. All PRO-CTCAE data were dichotomized into no symptoms versus symptoms of any grade, in order to ensure that the screener questions could be sensitive enough to capture even subtle symptoms that could be addressed in follow-up questions.

2.6 Recruitment and data collection procedures

At outpatient clinics, patients were prescreened for study eligibility with the clinical team. Eligibility criteria were the same as phase 1, except inclusion was expanded to include individuals with a head and neck cancer, a gastroesophageal or esophageal cancer, or a lung cancer that was being treated primarily with radiation or chemoradiation; these diagnoses are associated with high prevalences of dysphagia and odynophagia. Eligible patients were approached in clinic waiting areas and examination rooms prior to their appointments. The phase 2 electronic tablet–based questionnaire included...
either the 1-question or 2-question screener and the PRO-CTCAE-like comprehensive panel of follow-up questions (see Table 2, phase 2), a set of 9 questions designed to assess the feasibility and acceptability of implementing the survey in a clinical setting, clinico-demographic questions, and the EQ5D-3L. The total number of questions was 23 to 24, depending on whether the patient completed the 1-question or 2-question screener. Some phase 2 patients answered all the questions regardless of their answers to the screening questions, which allowed their data to be assessed for screener sensitivity/specificity. The remaining phase 2 patients only answered the follow-up questions when they were screen-positive; it was this latter set of patients that was administered the feasibility/acceptability survey. Cancer clinical data for patients was abstracted from the electronic medical records. Clinicians were not given the dysphagia data but were asked to manage their patients in a usual fashion.

2.7 Statistical analysis

For phase 2, sensitivities and specificities were calculated for the 1-question screener against the PRO-CTCAE-like follow-up questions. Using a strict definition, all follow-up questions had to be answered in the negative (“none” or “not at all”) for the patient to be considered to have either no dysphagia or no odynophagia (these 2 symptoms were assessed independently).

3 Results

3.1 Phases 1 and 2 description

Demographic and clinical characteristics are presented in Table 1. Figure 1 describes the recruitment and analysis details of the population, captured in a CONSORT diagram. Prevalence of dysphagia (Figure 2) based on screener questions was approximately 36% to 40%, regardless of whether it was assessed as the ability to eat (phase 1) or the presence of difficulty or pain upon swallowing (phase 2), and regardless of whether it was a 2-question or 1-question screener.

Proper evaluation of a screening tool requires a broad distribution of patients with and without swallowing issues. As expected, both phases 1 and 2 patients reported difficulty swallowing solid foods more often than soft/mashed foods or liquids. The median sumative SICV score was 17 (range: 2-20); one-quarter of patients fell below the 12.16 SICV, the mean value of patients who had suffered associated weight loss (Table 2).

3.2 Sensitivity and specificity of phase 1 screening questions

In phase 1, initial analysis found that screener 1, “How are you currently eating?”, with anchoring responses of “Able to eat normally” and “Unable to swallow anything,” had significantly better test characteristics (sensitivity/specificity) than screener 2, “I can swallow easily and naturally.” Sensitivities and specificities were evaluated against various gold-standard SICVs (Table 3). In screener 1, sensitivities ranged from 66% to 86%, and specificities ranged from 63% to 83%. Areas under the curve ranged from 0.752 to 0.885 (Figure 3). The sum of sensitivity and specificity was greatest when SICV of 12.16 was used as a gold standard cut-off (80% sensitivity and 75% specificity).

3.3 Sensitivity and specificity, feasibility, and acceptability of phase 2 screening questions

In phase 2, sensitivity and specificity were evaluated only on the 1-question screener (screener 5). When compared with the gold standard PRO-CTCAE questions on severity and functional interference for both dysphagia and odynophagia, the sensitivities ranged from 86% to 94% for each of the follow-up questions, while the specificities ranged from 93% to 100% (Table 3). The screener was slightly more sensitive and specific to difficulty swallowing than to pain swallowing (Table 3).

Feasibility and acceptability, and practicality of dysphagia symptom screening via electronic tablet, were assessed for both the 2-question (screeners 3 and 4) and 1-question (screener 5) dysphagia screeners based on responses of 208 of 255 total patients included in phase 2; missing results were because we selected a random sample for completion of this section. Not every patient was approached because of the added coordinator time to track and time patients, and of those who were asked to complete this section, 97% had complete data. Median completion time for the 2-question screener and follow-up questions was 127 seconds; this time was reduced to 107 seconds for the 1-question screener. Over 90% of patients completing both versions of the screener were willing to complete the surveys on a touchscreen tablet, did not feel like completing the surveys made their clinic visit more difficult, and did not find the questions to be upsetting or distressful. Over 80% felt that completing the surveys was not time consuming and that the completion of the surveys was a useful method to communicate with their clinician. However, less than 20% of patients wished to see or keep a printout of their dysphagia assessments (Figure S1).

![Image of a page from a document]
DISCUSSION

This study successfully identified several dysphagia screener questions that have potential use in screening for both observational studies and routine symptom assessment. The phase 1 screener (screener 1) provided a solid base for further investigation into dysphagia screener tools. It yielded sensitivity greater than 80% versus FACT-E at 3 SICVs (equal to 5.5, 7.1, and 12.16), suggesting that it is useful for screening for dysphagia in prospective observational studies. The 1-question screener (screener 5) developed and analyzed during phase 2 of the study was not only highly sensitive and specific when compared with our gold standard (PRO-CTCAE-like follow-up questions) but was also feasible and acceptable for use in routine multidisciplinary care. When symptoms were in the mild to very severe range that is consistent with a need for clinical intervention, the sensitivity and specificity of the screener were high (>85% all values). Further, the screener and follow-up questions, on average, took less than 2 minutes to complete, suggesting that the tool is practical for implementation in busy outpatient cancer clinics. Our analysis of the feasibility/acceptability responses by patients provides strong evidence that the tool minimizes patient burden, is easy for patients to use and understand, and improves communication of dysphagia symptoms between patient and clinician. The phase 2 screener (screener 5) may be an effective way to accurately detect the presence and assess the extent of patients’ dysphagia symptoms without significantly increasing clinic burden.

Currently, PRO-CTCAE v1.0 is becoming more prevalent for toxicity evaluation. However, this tool only contains a single swallowing item, and while this may be sufficient for gathering toxicity information, it may not be enough for clinical management of symptoms. Our 6 focused assessment questions balance between extensive toxicity assessment and symptom control. These questions distinguish differences in difficulty and pain upon swallowing and describe the extent of severity and functional interference due to symptoms. Further, our follow-up is formatted in a PRO-CTCAE style, which allows for easy integration and comparison with other PRO-CTCAE items.

This study supports the findings of prior studies that suggest that short screener tools can effectively assess cancer-related symptoms and reduce outpatient clinic burden. This study, however, is the only one, to our knowledge, to develop a highly sensitive and
specific screening tool explicitly for dysphagia/odynophagia. While more than one-third of patients included in this study responded positively to screeners for dysphagia, swallowing disturbances are often not assessed in an outpatient clinic setting. For example, outpatient cancer clinics in Ontario routinely assess symptoms with the Edmonton Symptom Assessment System46; this tool collects data on 9 common cancer symptoms, but dysphagia and odynophagia are not included. Our results suggest that the chosen phase 2 single screener question will be a highly effective clinical monitoring tool.

A recent randomized clinical trial (RCT) by Basch et al47 reported increased overall survival in a randomized trial where the experimental arm had received rapid symptom screening (in the form of PRO-CTCAE) and subsequent management, when compared with a control arm of patients receiving “usual” care. Thus, implementation of our screener routinely may have far-reaching effects beyond improving HRQoL.

This study was not without limitations. Consenting patients were fluent in English, so this study does not suggest that our tool, as it currently exists, is generalizable to patients who speak other

### TABLE 2  Distribution of answers to comprehensive gold standard questions on dysphagia and odynophagia

|                      | Phase 1 (N = 178) | Phase 2 (N > 90) |
|----------------------|-------------------|------------------|
|                      | Very much | Quite a bit | Somewhat | A little bit | Not at all |
| "I have difficulty swallowing solid foods" | 26 (15%) | 25 (14%) | 28 (16%) | 31 (17%) | 68 (38%) |
| "I have difficulty swallowing soft or mashed foods" | 6 (3%) | 12 (7%) | 25 (14%) | 25 (14%) | 110 (62%) |
| "I have difficulty swallowing liquids" | 4 (2%) | 10 (6%) | 13 (7%) | 24 (13%) | 127 (71%) |
| "I choke when I swallow" | 2 (1%) | 7 (4%) | 16 (9%) | 26 (15%) | 127 (71%) |
| "I can swallow naturally and easily" | 61 (34%) | 40 (22%) | 33 (19%) | 25 (14%) | 19 (11%) |

|                      | Very much | Quite a bit | Somewhat | A little bit | Not at all |
|----------------------|------------------|
| Severity of difficulty swallowinga | 3 (2%) | 8 (6%) | 45 (34%) | 36 (27%) | 42 (31%) |
| Difficulty upon swallowing – Solid food interference | 5 (4%) | 18 (15%) | 22 (18%) | 29 (24%) | 45 (38%) |
| Difficulty upon swallowing – Fluids interference | 2 (2%) | 5 (5%) | 5 (5%) | 29 (31%) | 53 (56%) |
| Severity of pain swallowinga | 1 (1%) | 8 (8%) | 14 (15%) | 16 (17%) | 57 (50%) |
| Pain upon swallowing – Solid food interference | 1 (1%) | 8 (9%) | 10 (11%) | 14 (15%) | 58 (64%) |
| Pain upon swallowing – Fluids interference | 0 (0%) | 6 (6%) | 3 (3%) | 16 (17%) | 69 (73%) |

a For these questions on severity, the category levels (from left to right) are severe, very severe, moderate, mild, none.

b Because not all patients were required to complete every component of phase 2, the sample size for each specific question ranged from 91 through 134 patients. Shaded boxes refer to the answer associated with lack of symptoms.
TABLE 3  Assessment of sensitivities and specificities of screening questions in phases 1 and 2<sup>a</sup>

| Cut-off values for gold standard | Prevalence of having swallowing difficulty using this cut-off | True positive | True negative | False positive | False negative | Sensitivity | Specificity |
|---------------------------------|------------------------------------------------------------|---------------|---------------|----------------|----------------|-------------|-------------|
| SICV 5.5                        | 3.9%                                                       | 6             | 108           | 63             | 1              | 86%         | 63%         |
| 7.1                             | 10.1%                                                      | 15            | 106           | 54             | 3              | 83%         | 66%         |
| 12.16                           | 25.3%                                                      | 36            | 100           | 33             | 9              | 80%         | 75%         |
| 13.3                            | 32.0%                                                      | 44            | 96            | 25             | 13             | 77%         | 79%         |
| 14.5                            | 37.6%                                                      | 48            | 90            | 21             | 19             | 72%         | 81%         |
| 16                              | 44.4%                                                      | 52            | 82            | 17             | 27             | 66%         | 83%         |

Phase 1: screener 1, "How are you currently eating"

| Cut-off values for gold standard | Prevalence of having swallowing difficulty using this cut-off | True positive | True negative | False positive | False negative | Sensitivity | Specificity |
|---------------------------------|------------------------------------------------------------|---------------|---------------|----------------|----------------|-------------|-------------|
| SICV 5.5                        | 3.9%                                                       | 3             | 98            | 73             | 2              | 71%         | 57%         |
| 7.1                             | 10.1%                                                      | 12            | 96            | 64             | 6              | 67%         | 60%         |
| 12.16                           | 25.3%                                                      | 30            | 85            | 48             | 15             | 67%         | 64%         |
| 13.3                            | 32.0%                                                      | 35            | 80            | 41             | 22             | 61%         | 66%         |
| 14.5                            | 37.6%                                                      | 40            | 78            | 33             | 27             | 60%         | 70%         |
| 16                              | 44.4%                                                      | 45            | 75            | 24             | 34             | 57%         | 76%         |

Phase 2 single question screener: difficulty swallowing question

No None/not at all in all subsequent questions vs all others 61 33 0 4 94% 100%

Phase 2 single question screener: pain swallowing question

None/not at all in all subsequent questions only vs all others 24 38 3 4 86% 93%

Abbreviation: SICV, Swallowing Index Cut-off Value.

<sup>a</sup>For phase 1, screener 1, response choices were "normal," "eats soft food only," "eats pureed food only," "drinks liquid only," and "no swallowing at all."

FIGURE 3  Receiver operator curves for various cutoffs of the FACT-E swallowing index (Swallowing Index Cut-off Value [SICV]). Area under the curve (AUC) ranges from 0.752 to 0.885
languages. Future validation in multiple languages would be important. In phase 1, we identified a screener question that would allow our patients to be dichotomized into those with and without dysphagia when using FACT-E; we should caution that researchers who want to use the full scale of FACT-E or analyze the data in a continuous manner should continue to use FACT-E in its current state. Our study made no direct comparisons of the screener’s effectiveness between the 3 groups included (head and neck, gastroesophageal cancers, and thoracic cancers undergoing radiation); however, the 1-question screener was extremely straightforward and direct, so it is highly unlikely that the characteristics of our test would noticeably change across disease sites. We also did not assess clinician perceptions directly, as we tried to avoid clinician bias in influencing patient perception; instead, we avoided providing the clinicians with the dysphagia results completely and asked them to manage their patients in a usual fashion. Finally, there is still controversy as to whether the gold standard reporting of symptoms or toxicities should be "filtered" through a clinician’s viewpoint (ie, physician interpretation of an open discussion of toxicities) or be directly ascertained from the patient using PROs; our study used the patient-reported symptoms and toxicity as the gold standard.

Our study determined 2 highly sensitive (>85% sensitivity phase 1 and >90% sensitivity phase 2) screener questions for swallowing issues. One screener was designed for use in research settings, as it was designed for use instead of FACT-E. The second screener was designed with a different purpose in mind: for routine clinical use. The screeners were neither burdensome on patients nor time consuming. Future studies should look to assess the practical implication of our screener in populations of non-English-speaking patients in outpatient clinics. Comparison to other gold standard research tools for dysphagia should also be considered. In the meantime, we have established, in principle, the utility of implementing single-question screeners in both the observational study setting and for routine clinical practice. We expect to reduce survey burden in patients by reducing the number of patients who need to complete the more extensive follow-up questions that will refine the degree, frequency, and severity of symptoms required to manage these symptoms properly in the clinical setting.

ACKNOWLEDGMENTS
This research was funded by Cancer Care Ontario through the Ontario Patient Reported Outcomes of Symptoms and Toxicity (ON‐PROST) and the Alan B. Brown Chair, Princess Margaret Cancer Foundation.

CONFLICT OF INTEREST
None.

AUTHOR CONTRIBUTIONS
Conceptualization: Geoffrey Liu, Mark Doherty, Catherine Brown, Wei Xu, Doris Howell
Data curation: Michael Borean, Kishan Shani, Catherine Brown, Geoffrey Liu, Gail Darling, Rebecca K. Wong, Raymond Jang, Elena Elimova, Grainne O’Kane
Formal analysis: Michael Borean, Kishan Shani, Catherine Brown, Wei Xu, Geoffrey Liu

Funding acquisition: Geoffrey Liu, Doris Howell
Investigation: Michael Borean, Kishan Shani, Judy Chen, Mindy Liang, Joel Karkada
Methodology: Michael Borean, Geoffrey Liu
Project administration: Geoffrey Liu
Resources: Geoffrey Liu, Doris Howell
Supervision: Geoffrey Liu, Wei Xu, M. Catherine Brown, Doris Howell
Visualization: Michael Borean, Kishan Shani, M. Catherine Brown, Geoffrey Liu
Writing – Original Draft Preparation: Michael Borean
Writing – Review and Editing: Michael Borean, Kishan Shani, M. Catherine Brown, Judy Chen, Mindy Liang, Joel Karkada, Simranjit Kooner, Mark Doherty, Grainne M O’Kane, Dr. Raymond Jang, Elena Elimova, Rebecca K Wong, Gail Darling, Wei Xu, Doris Howell, Geoffrey Liu

ORCID
Michael Borean http://orcid.org/0000-0003-4414-8691

REFERENCES
1. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. In: Services Hah, ed 2009
2. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. JNCI Monographs. 2007;2007(37):16-21
3. Cleeland CS, Bennett GJ, Dantzler R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919-2925
4. Glover J, Dibble SL, Dodd MJ, Miaskowski C. Mood states of oncology outpatients: Does pain make a difference? J Pain Symptom Manage. 1995;10(2):120-128
5. Burrows M, Dibble SL, Miaskowski C. Differences in outcomes among patients experiencing different types of cancer-related pain. Oncol Nurs Forum. 1998;25(4):735-741
6. Miaskowski C, Lee KA, Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage. 1999;17(5):320-332
7. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001;28(3):465-470
8. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(6 Suppl):1684-1688
9. Valentine AD, Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer. 2001;92(6 Suppl):1694-1698
10. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol. 1998;25(1 Suppl 1):3-8
11. Cleeland CS. Cancer-related symptoms. Semin Radiat Oncol. 2000;10(3):175-190
12. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet (London, England). 2003;362(9384):640-650
13. Berger A. Treating fatigue in cancer patients. Oncologist. 2003;8(Suppl 1):10-14
14. Bernard S, Gill P, Rosen P, et al. A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Med Pediatr Oncol. 1991;19(4):276-282
15. Manzullo E, Liu W, Escalante C. Treatment for cancer-related fatigue: an update. Expert Rev Anticancer Ther. 2003;3(1):99-106.
16. Jacobsen PB, Donovan KA, Weitzner MA. Distinguishing fatigue and depression in patients with cancer. *Semin Clin Neuropsychiatry*. 2003;8(4):229-240.

17. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. *Cancer*. 2003;98(9):1786-1801.

18. ten Tije AJ, Smorenburg CH, Seynavee C, et al. Weekly pacitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. *Eur J Cancer (Oxford, England)*. 1990;2004;40(3):352-357.

19. Bagha SM, Macedo A, Jacks LM, et al. The utility of the Edmonton symptom assessment system in screening for anxiety and depression. *Eur J Cancer Care*. 2013;22(1):60-69.

20. Vodernaier A, Linden W, Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. *J Natl Cancer Inst*. 2009;101(21):1464-1488.

21. Ripamonti CI, Bandieri E, Pessi MA, Maruelli A, Buonacorso L, Miccinesi G. The Edmonton symptom assessment system (ESAS) as a screening tool for depression and anxiety in non-advanced patients with solid or haematological malignancies on cure or follow-up. *Support Care Cancer*. 2014;22(3):783-793.

22. Raber-Durlacher JE, Brennan MT, Verdonck-de Leeuw IM, et al. Swallowing dysfunction in cancer patients. *Support Care Cancer*. 2012;20(3):433-443.

23. Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia following treatment for head and neck cancer. *Anticancer Res*. 2005;25(4):2929-2934.

24. Mekhail TM, Adelstein DJ, Rybicki LA, Larto MA, Saxton JP, Lavertu P. Acute secondary effects in the esophagus in patients undergoing radiotherapy for carcinoma of the lung. *Am J Clin Oncol*. 1989;12(1):34-40.

25. Larsson M, Hedelin B, Johansson I, Athlin E. Eating problems and weight loss for patients with head and neck cancer: a chart review from diagnosis until one year after treatment. *Cancer Nurs*. 2005;28(6):425-435.

26. Layke JC, Lopez PP. Esophageal cancer: a review and update. *Am Fam Physician*. 2006;73(12):2187-2194.

27. Mascarenhas F, Silvestre ME, Da Costa M, Grina N, Campos C, Chaves P. Acute secondary effects in the esophagus in patients undergoing radiotherapy for carcinoma of the lung. *Am J Clin Oncol*. 1989;12(1):34-40.

28. Obbairuius A, van Maasakkers L, Baver L, et al. Standardization of health outcomes assessment for depression and anxiety: recommendations from the ICHOM depression and anxiety working group. *Qual Life Res Int J Qual Life Asp Treat Care Rehab*. 2017;26(12):3211-3225.

29. Darling G, Eton DT, Sullivan J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. *Cancer*. 2006;107(4):854-863.

30. O’Rourke I, Tiver K, Bull C, Gabski V, Langlands A. Swallowing performance after radiation therapy for carcinoma of the esophagus. *Cancer*. 1988;61(10):1801-1805.

31. Brooks R. EuroQol: the current state of play. *Health Policy (Amsterdam, Netherlands)*. 1996;37(1):53-72.

32. Wang T. Active Surveillance of skin toxicities through web-based patient-reported (PRO) toxicity reporting tool in outpatient cancer patients on EGFR tyrosine kinase inhibitors (TKI): a feasibility study. *Poster presented at Conference on Pharmacoeconomics & Therapeutic Risk Management; August, 2015; Boston, USA*.

33. Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet (London, England)*. 2015;386(9998):1049-1056.

34. Krekelers BN, Broadfoot CK, Johnson S, Connor NP, Rogus-Pulia N. Patient adherence to dysphagia recommendations: a systematic review. *Dysphagia*. 2017.

35. Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. *Nat Rev Clin Oncol*. 2016;13(5):319-325.

36. Dudgeon D, King S, Howell D, et al. Cancer Care Ontario’s experience with implementation of routine physical and psychological symptom distress screening. *Psychooncology*. 2012;21(4):357-364.

37. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA*. 2017;318(2):197-198.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.